226 related articles for article (PubMed ID: 2686418)
21. Ciprofloxacin versus ceftazidime in skin and soft tissue infections.
Thadepalli H; Mathai D; Chuah SK; Bansal MB
J Chemother; 1989 Feb; 1(1):30-4. PubMed ID: 2656929
[TBL] [Abstract][Full Text] [Related]
22. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.
Davis C
Clin Ther; 1994; 16(3):505-21. PubMed ID: 7923317
[TBL] [Abstract][Full Text] [Related]
23. Ciprofloxacin: an update on clinical experience.
Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
[TBL] [Abstract][Full Text] [Related]
24. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
25. Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections.
Cox CE
Am J Med; 1993 Mar; 94(3A):118S-125S. PubMed ID: 8452167
[TBL] [Abstract][Full Text] [Related]
26. A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever.
Bayston KF; Want S; Cohen J
Am J Med; 1989 Nov; 87(5A):269S-273S. PubMed ID: 2686428
[TBL] [Abstract][Full Text] [Related]
27. Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime.
Parish LC; Asper R
Am J Med; 1987 Apr; 82(4A):227-9. PubMed ID: 3555041
[TBL] [Abstract][Full Text] [Related]
28. [Comparative study of cefpirome and ceftazidime in complicated urinary tract infections].
Naide Y; Aso Y; Oshi M; Kumamoto Y; Hirose T; Machida T; Tsuchida S; Suzuki K; Orikasa S; Kawada Y
Hinyokika Kiyo; 1991 Apr; 37(4):447-64. PubMed ID: 1892004
[TBL] [Abstract][Full Text] [Related]
29. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.
Neu HC; Davidson S; Briones F
Am J Med; 1989 Nov; 87(5A):209S-212S. PubMed ID: 2511758
[TBL] [Abstract][Full Text] [Related]
30. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
Brown AE; Smith G
Am J Med; 1989 Nov; 87(5A):266S-268S. PubMed ID: 2589376
[TBL] [Abstract][Full Text] [Related]
31. Intravenous ciprofloxacin therapy in severe infections.
Gudiol F; Cabellos C; Pallares R; Linares J; Ariza J
Am J Med; 1989 Nov; 87(5A):221S-224S. PubMed ID: 2589364
[TBL] [Abstract][Full Text] [Related]
32. Treatment of skin, skin structure, bone, and joint infections with ceftazidime.
Gentry LO
Am J Med; 1985 Aug; 79(2A):67-74. PubMed ID: 3895921
[TBL] [Abstract][Full Text] [Related]
33. Treatment of serious infections with intravenous ciprofloxacin.
Scully BE; Neu HC
Am J Med; 1987 Apr; 82(4A):369-75. PubMed ID: 3555062
[TBL] [Abstract][Full Text] [Related]
34. Prospective, controlled, randomized non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of skin or soft-tissue infections.
Dominguez J; Palma F; Vega ME; Magaña JL; Ortiz G; Teresa-Hojyo M; Dominguez L
Am J Med; 1989 Nov; 87(5A):136S-137S. PubMed ID: 2686414
[No Abstract] [Full Text] [Related]
35. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
36. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.
Paladino JA; Sperry HE; Backes JM; Gelber JA; Serrianne DJ; Cumbo TJ; Schentag JJ
Am J Med; 1991 Nov; 91(5):462-70. PubMed ID: 1951408
[TBL] [Abstract][Full Text] [Related]
37. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
[TBL] [Abstract][Full Text] [Related]
38. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group.
Sieger B; Berman SJ; Geckler RW; Farkas SA
Crit Care Med; 1997 Oct; 25(10):1663-70. PubMed ID: 9377880
[TBL] [Abstract][Full Text] [Related]
39. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.
Giamarellou H; Bassaris HP; Petrikkos G; Busch W; Voulgarelis M; Antoniadou A; Grouzi E; Zoumbos N
Antimicrob Agents Chemother; 2000 Dec; 44(12):3264-71. PubMed ID: 11083625
[TBL] [Abstract][Full Text] [Related]
40. Intravenous fleroxacin versus ceftazidime for lower respiratory tract and skin and soft-tissue infections.
Huston MJ; Lentino JR
Clin Ther; 1992; 14(4):595-602. PubMed ID: 1525793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
